With over 7000 square feet of dedicated research lab space, and a highly accomplished research faculty, ARCOM students will have the opportunity to engage in cutting edge biomedical research. Read more about ongoing medical research at ARCOM and faculty mentors below.
Ross E. Longley, PhD
The overall goal of my research is to discover agents which stimulate and/or regulate the in vitro antitumor activity of immunological cells known as natural killer or “NK” cells (1). A chemically diverse universe of substances known as natural products derived from terrestrial plants and microbes have been shown to possess potent drug-like activities and have been used as chemical scaffolds to develop new agents which have proven to be effective drugs in fighting various types of cancer (2). My lab is involved in the screening of various microbial and plant-derived extracts which will yield compounds whose biological activities stimulate and/or regulate the in vitro, anti-cancer activity of NK cells which results in an enhanced anti-tumor effect. Extracts which are found to be stimulatory to NK cell activity undergo further chemical extraction and purification by our collaborators, and the resulting fractions and pure compounds are further assayed for NK cell activity using flow cytometry. Those compounds which enhance or modulate NK cell activity are further identified as to their chemical structure and their mechanism of action by our collaborators.
- Maelig, G M., and Lanier, L.L. 2016. NK cells and cancer: you can teach innate cells new tricks. Nature Reviews Cancer 16: pp 7-9.
- Longley, R.E. 2012. Discodermolide: Past, present and future. In: Natural products drug discovery. (Frank Koehn, ed.). Springer, New York, NY.
Kenneth Hensley, PhD
My research has long focused on mechanisms of neurodegeneration in diseases including Alzheimer’s disease (HD); amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD). I am interested in why neurons deteriorate, rather than how they die. I cannot resurrect a dead neuron but if I can understand why neurons get sick, I might be able to support natural repair pathways in order to improve their health and reduce or even reverse incipient neurodegeneration. Over the past twenty-five years this philosophy has led me to explore many aspects of neuroinflammation, signal transduction and cytoskeletal regulation. One of the most significant outcomes of this effort has been my discovery of a natural brain amino acid metabolite called lanthionine ketimine (LK), which is produced by non-canonical reactions of vitamin B-dependent transulfuration pathway enzymes. My research indicates that both LK and a synthetic, bioavailable LK-ester deriviative (LKE) can suppress neuroinflammation in the damaged brain and support healthy neuron function through the novel mechanism of inhibiting cyclin dependent kinase-5/p25 (Cdk5/p25). My colleagues and I have shown that LKE reduces pathology and restores neural function in rodent models of ALS, AD, stroke, and spinal cord injury. These findings have been published in Biochemistry; Journal of Neuroscience; Journal of Neuropathology and Experimental Neurology; Journal of Neurochemistry; Journal of Neuroscience Research; and other forums. In 2013 I co-founded a company called XoNovo Ltd. to develop LKE as an experimental therapeutic for human brain disease. LKE, now also known as XN-001, is in late-stage preclinical development with an IND application under preparation. The initial clinical target for XN-001 is the pediatric neurodegenerative condition of Batten disease (juvenile neuronal ceroid lipofuscinosis).
I have long enjoyed mentoring undergraduate, graduate and medical students who have contributed to my research projects and co-authored many scientific manuscripts resulting from their work. I plan to continue this practice as I work with local and regional university partners to create new opportunities for undergraduate biomedical research. I feel that ARCOM and its regional academic research partners can synergize in powerful ways to accomplish much greater goals than could be achieved separately. Through such strategic collaborations I hope to help build new models for the conduct of significant biomedical research at Osteopathic medical schools. These goals include discovering and disseminating new knowledge, but primarily emphasize the mission of teaching the practice of evidence-based science to regional students who are likely to matriculate into medical school or otherwise contribute to the 21st century biomedical enterprise.
Eric Lee, PhD
My research is centered around the role of chronic inflammation in diabetes with two specific areas of interests: 1. The etiology of type II diabetes, and 2. Diabetes complications related to non-healing diabetic ulcers. The etiology based research is focused on the relationship between macrophages and adipocytes in the development of insulin insensitivity with emphasis on the role of IkB-β in crosstalk between inflammatory and insulin cell signaling. The diabetic complications research is focused on developing an understanding the role of IL-6, advanced glycation end-products, and receptors for advanced glycation end-products in the inflammatory phase of delayed diabetic wound healing and diabetic ulcers.
Lance Bridges, PhD
Cell adhesion and migration are integral in a spectrum of biological processes including fertilization, embryonic development, wound healing, cancer metastasis, and immune function. Specifically, the Bridges lab focuses on the role of ADAM (a disintegrin and metalloprotease) proteins in immune cell trafficking. ADAMs are cell surface and soluble glycoproteins uniquely exhibiting both adhesive and proteolytic properties. Catalytically active ADAMs are well-established ectodomain sheddases capable of transforming latent cell-bound substrates to soluble, biologically active derivatives. The sheddase role of ADAMs in processing biologically decisive molecules such as amyloid precursor protein (APP), GPCR activators, cytokines such as TNF-α, and growth factors, has established that dysregulation of ADAM function is detrimental to normal cell function and promotes disease.
The Bridges lab is working on how ADAM-mediate shedding is naturally regulated. The first aspect of this project posits that noncatalytic ADAMs may compete for cellular factors to govern ADAM shedding. Strikingly, of the 21 human ADAMs, nearly half (8/21) inexplicably lack the consensus site required for catalysis. The novel model of regulation tentatively termed “competitive mimicry” may account for the abundance of these “dead” enzymes (see figure below). The second aspect entails metabolic regulation of lymphocyte metalloprotease mediated shedding. Specifically, the role of retinoids, natural and synthetic derivatives of vitamin A, in ADAM regulation is being pursued. The necessity of vitamin A for the proper establishment and maintenance of immunity has long been appreciated, but the precise role of vitamin A in immunity has only begun to be elucidated within the past decade. The Bridges lab has demonstrated that vitamin A oxidative metabolites stimulate immune cell adhesion to select ADAMs through two functionally distinct mechanisms. Currently, investigation into how exposure to metabolites translates into cell adhesion with respect to signal transduction and adhesion receptor expression in context of cutaneous T cell lymphoma are underway.
Rakesh K. Singh, PhD
Methotrexate (Otrexup, Rasuvo, Rheumatrex, Trexall) is a disease-modifying anti-rheumatic drug (DMARD) approved for the treatment of adults with Rheumatoid Arthritis (RA). It has become the cornerstone of RA treatment since it was first introduced over five decades ago as an anti-cancer drug. It is extensively prescribed in Juvenile Idiopathic Arthritis (JIA), however, treatment is mired by a delayed onset of action and a highly variable and unpredictable response profile.
My research is focused on understanding the role of the JAK/STAT pathway in the anti-inflammatory activity of MTX. Initial findings using fibroblast-like synoviocytes (FLS) isolated from JIA patients suggest that 24-48 hour incubation with MTX can inhibit an active JAK/STAT pathway. Also, in cells with no constitutive JAK/STAT activity, pre-incubation with MTX for 24 hour can prevent IL-6 stimulated activation of JAK/STAT pathway.
Future research goals include confirming inhibitory activity of MTX on JAK/STAT pathway in physiologically relevant systems like peripheral blood mononuclear cell (PBMCs) and teasing out the biochemical interactions responsible for inhibition of JAK/STAT activity.
Zachary Throckmorton, PhD
I am a biological anthropologist by training, with research interests in human anatomical variation and evolution. As a paleoanthropologist, I study the human fossil record to better understand the patterns and processes by which our species evolved from ancient quadrupedal ancestors into our modern bipedal form. My research specialty is evolution of the lower limb generally and the foot and ankle specifically.
In 2014, soon after I earned my PhD, I had the tremendous fortune to be invited to the Rising Star Workshop at the University of the Witwatersrand’s Evolutionary Studies Institute in Johannesburg, South Africa. Our international team of researchers was tasked with describing and analyzing one of the most astounding hauls of hominin (human ancestor) fossils ever discovered. We concluded the fossils were from a previously unknown species which we named Homo naledi and published in the journals eLife and Nature Communications. This research was featured in news headlines around the world, made the covers of National Geographic, Scientific American, and Discover magazines, and was the subject of the NOVA/PBS National Geographic documentary “Dawn of Humanity.”
I am also a member of the international team that identified and described fossil SK 7923, a hominin metatarsal from a different South African paleoanthropological excavation site (Swartkrans). An otherwise unremarkable specimen, we recognized this foot bone presented a malignant osteosarcoma. Because it is dated to nearly 2 million years old, it is the oldest known case of human cancer.
While my research on the human fossil record is ongoing, I also enjoy mentoring students in projects documenting and analyzing patterns of muscle variation and evolution. We have presented our research at multiple national conferences.
Abby L. Geis, PhD
My research broadly centers on the connection between gut bacteria, the major constituent of the human microbiota, and host health. Specifically, I am interested in the ways bacterial-derived products, such as respiratory waste or toxins, may influence the activation status and function of host immune cells. This includes the exploration of host dietary supplements that have the potential to mitigate overt immune activation, and even impart regulatory immune function.
In order to compress these complex relationships into a more investigable system, and to reduce our dependence on extensive animal models, we are working on a continuous human microbiota culture system, or chemostat. The chemostat simulates the human gut and enables us to investigate distinct microbiotas, and their products, in a fairly high-throughput fashion. It also enables us to restrict the bacterial composition to defined input species. Thus, we anticipate the discovery of unique bacterial species-derived products that we can add to cultures of human peripheral blood mononuclear cells to probe immune responsiveness.